84 related articles for article (PubMed ID: 31049795)
1. Mutation analysis of POLE gene in patients with early-onset colorectal cancer revealed a rare silent variant within the endonuclease domain with potential effect on splicing.
Lasabová Z; Kalman M; Holubeková V; Grendár M; Kašubová I; Jašek K; Meršaková S; Malicherová B; Baranenko D; Adamek M; Kruzliak P; Plank L
Clin Exp Med; 2019 Aug; 19(3):393-400. PubMed ID: 31049795
[TBL] [Abstract][Full Text] [Related]
2. Somatic POLE exonuclease domain mutations are early events in sporadic endometrial and colorectal carcinogenesis, determining driver mutational landscape, clonal neoantigen burden and immune response.
Temko D; Van Gool IC; Rayner E; Glaire M; Makino S; Brown M; Chegwidden L; Palles C; Depreeuw J; Beggs A; Stathopoulou C; Mason J; Baker AM; Williams M; Cerundolo V; Rei M; Taylor JC; Schuh A; Ahmed A; Amant F; Lambrechts D; Smit VT; Bosse T; Graham TA; Church DN; Tomlinson I
J Pathol; 2018 Jul; 245(3):283-296. PubMed ID: 29604063
[TBL] [Abstract][Full Text] [Related]
3. Ultra-mutated colorectal cancer patients with POLE driver mutations exhibit distinct clinical patterns.
Hu H; Cai W; Wu D; Hu W; Dong Wang L; Mao J; Zheng S; Ge W
Cancer Med; 2021 Jan; 10(1):135-142. PubMed ID: 33125191
[TBL] [Abstract][Full Text] [Related]
4. Mutations in POLE and survival of colorectal cancer patients--link to disease stage and treatment.
Stenzinger A; Pfarr N; Endris V; Penzel R; Jansen L; Wolf T; Herpel E; Warth A; Klauschen F; Kloor M; Roth W; Bläker H; Chang-Claude J; Brenner H; Hoffmeister M; Weichert W
Cancer Med; 2014 Dec; 3(6):1527-38. PubMed ID: 25124163
[TBL] [Abstract][Full Text] [Related]
5. Pathological complete response to immune checkpoint inhibitor in patients with colorectal cancer liver metastases harboring
Wen L; Chen Z; Ji X; Fong WP; Shao Q; Ren C; Cai Y; Li B; Yuan Y; Wang D; Li Y
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35793867
[TBL] [Abstract][Full Text] [Related]
6. Exploring the basis of heterogeneity of cancer aggressiveness among the mutated POLE variants.
Selves J; de Castro E Gloria H; Brunac AC; Saffi J; Guimbaud R; Brousset P; Hoffmann JS
Life Sci Alliance; 2024 Jan; 7(1):. PubMed ID: 37891003
[TBL] [Abstract][Full Text] [Related]
7. Exploring Co-occurring POLE Exonuclease and Non-exonuclease Domain Mutations and Their Impact on Tumor Mutagenicity.
Shah SM; Demidova EV; Ringenbach S; Faezov B; Andrake M; Gandhi A; Mur P; Viana-Errasti J; Xiu J; Swensen J; Valle L; Dunbrack RL; Hall MJ; Arora S
Cancer Res Commun; 2024 Jan; 4(1):213-225. PubMed ID: 38282550
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive analysis of POLE and POLD1 Gene Variations identifies cancer patients potentially benefit from immunotherapy in Chinese population.
Yao J; Gong Y; Zhao W; Han Z; Guo S; Liu H; Peng X; Xiao W; Li Y; Dang S; Liu G; Li L; Huang T; Chen S; Song L
Sci Rep; 2019 Oct; 9(1):15767. PubMed ID: 31673068
[TBL] [Abstract][Full Text] [Related]
9. Proofreading the way: immune checkpoint inhibitors in polymerase ε/polymerase δ (POLE/POLD1)-altered colorectal cancer.
Cecchini M; Sundar R
Ann Oncol; 2024 Jul; 35(7):582-584. PubMed ID: 38910015
[No Abstract] [Full Text] [Related]
10. Molecular profiling and sequential somatic mutation shift in hypermutator tumours harbouring POLE mutations.
Hatakeyama K; Ohshima K; Nagashima T; Ohnami S; Ohnami S; Serizawa M; Shimoda Y; Maruyama K; Akiyama Y; Urakami K; Kusuhara M; Mochizuki T; Yamaguchi K
Sci Rep; 2018 Jun; 8(1):8700. PubMed ID: 29880869
[TBL] [Abstract][Full Text] [Related]
11. POLE-Mutant Colon Adenocarcinoma-Case Presentation and Histopathological Evaluation.
Pancsa T; Vasas B; Melegh Z; Tóth E; Torday L; Sejben A
J Gastrointest Cancer; 2024 Jun; 55(2):961-964. PubMed ID: 38175383
[TBL] [Abstract][Full Text] [Related]
12. Multiple duodenal epithelial tumors in a patient with polymerase proofreading-associated polyposis in POLE variant.
Miyazaki H; Dohi O; Maeda E; Tomioka A; Yoshida N; Morinaga Y; Itoh Y; Ishikawa H
Clin J Gastroenterol; 2024 Jun; 17(3):425-428. PubMed ID: 38386255
[TBL] [Abstract][Full Text] [Related]
13. TTN/OBSCN 'Double-Hit' predicts favourable prognosis, 'immune-hot' subtype and potentially better immunotherapeutic efficacy in colorectal cancer.
Liu Z; Wang L; Guo C; Liu L; Jiao D; Sun Z; Wu K; Zhao Y; Han X
J Cell Mol Med; 2021 Apr; 25(7):3239-3251. PubMed ID: 33624434
[TBL] [Abstract][Full Text] [Related]
14. Solving the enigma of POLD1 p.V295M as a potential cause of increased cancer risk.
Mur P; Magraner-Pardo L; García-Mulero S; Díez-Villanueva A; Del Valle J; Ezquerro E; Lázaro C; Capellá G; Moreno V; Sanz-Pamplona R; Pons T; Valle L
Eur J Hum Genet; 2022 Apr; 30(4):485-489. PubMed ID: 34285382
[TBL] [Abstract][Full Text] [Related]
15. Correction: Exploring Co-occurring POLE Exonuclease and Non-exonuclease Domain Mutations and Their Impact on Tumor Mutagenicity.
Shah SM; Demidova EV; Ringenbach S; Faezov B; Andrake M; Gandhi A; Mur P; Viana-Errasti J; Xiu J; Swensen J; Valle L; Dunbrack RL; Hall MJ; Arora S
Cancer Res Commun; 2024 May; 4(5):1398. PubMed ID: 38819318
[No Abstract] [Full Text] [Related]
16. Cancers from Novel
Galati MA; Hodel KP; Gams MS; Sudhaman S; Bridge T; Zahurancik WJ; Ungerleider NA; Park VS; Ercan AB; Joksimovic L; Siddiqui I; Siddaway R; Edwards M; de Borja R; Elshaer D; Chung J; Forster VJ; Nunes NM; Aronson M; Wang X; Ramdas J; Seeley A; Sarosiek T; Dunn GP; Byrd JN; Mordechai O; Durno C; Martin A; Shlien A; Bouffet E; Suo Z; Jackson JG; Hawkins CE; Guidos CJ; Pursell ZF; Tabori U
Cancer Res; 2020 Dec; 80(24):5606-5618. PubMed ID: 32938641
[No Abstract] [Full Text] [Related]
17. Comprehensive Analysis of Hypermutation in Human Cancer.
Campbell BB; Light N; Fabrizio D; Zatzman M; Fuligni F; de Borja R; Davidson S; Edwards M; Elvin JA; Hodel KP; Zahurancik WJ; Suo Z; Lipman T; Wimmer K; Kratz CP; Bowers DC; Laetsch TW; Dunn GP; Johanns TM; Grimmer MR; Smirnov IV; Larouche V; Samuel D; Bronsema A; Osborn M; Stearns D; Raman P; Cole KA; Storm PB; Yalon M; Opocher E; Mason G; Thomas GA; Sabel M; George B; Ziegler DS; Lindhorst S; Issai VM; Constantini S; Toledano H; Elhasid R; Farah R; Dvir R; Dirks P; Huang A; Galati MA; Chung J; Ramaswamy V; Irwin MS; Aronson M; Durno C; Taylor MD; Rechavi G; Maris JM; Bouffet E; Hawkins C; Costello JF; Meyn MS; Pursell ZF; Malkin D; Tabori U; Shlien A
Cell; 2017 Nov; 171(5):1042-1056.e10. PubMed ID: 29056344
[TBL] [Abstract][Full Text] [Related]
18. Defining the subset of mutations in polymerase epsilon (POLE) associated with loss-of-proofreading (LOP) functionality.
Maddalena G; Zeineddine FA; Rivero-Hinojosa S; Aushev VN; Chowdhury S; Zeineddine MA; Yousef AM; Yap TA; EINaggar AC; Liu MC; White M; Overman MJ; Kopetz S; Shen JP
Ann Oncol; 2024 Jul; 35(7):678-680. PubMed ID: 38734075
[No Abstract] [Full Text] [Related]
19. Molecular genetics of early-onset colorectal cancer.
Marx O; Mankarious M; Yochum G
World J Biol Chem; 2023 Mar; 14(2):13-27. PubMed ID: 37034132
[TBL] [Abstract][Full Text] [Related]
20. Distinct clinical pattern of colorectal cancer patients with POLE mutations: A retrospective study on real-world data.
Jiang M; Jia Y; Han J; Shi J; Su C; Zhang R; Xing M; Jin S; Zong H
Front Genet; 2022; 13():963964. PubMed ID: 36479248
[No Abstract] [Full Text] [Related]
[Next] [New Search]
